Serum Müllerian inhibiting substance levels are lower in premenopausal women with breast precancer and cancer

4Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Background: In preclinical studies, müllerian inhibiting substance (MIS) has a protective affect against breast cancer. Our objective was to determine whether serum MIS concentrations were associated with cancerous or precancerous lesions. Blood from 30 premenopausal women was collected and serum extracted prior to their undergoing breast biopsy to assess a suspicious lesion found on imaging or physical examination. Based on biopsy results, the serum specimens were grouped as cancer (invasive or ductal carcinoma in situ), precancer (atypical hyperplasia or lobular carcinoma in situ), or benign. Findings: Serum from women with cancer and precancer (p = .0009) had lower MIS levels than serum from women with benign disease.

Cite

CITATION STYLE

APA

McCoy, A. C., Kliethermes, B., Zhang, K., Qin, W., Sticca, R., Bouton, M., & Sauter, E. R. (2011). Serum Müllerian inhibiting substance levels are lower in premenopausal women with breast precancer and cancer. BMC Research Notes, 4. https://doi.org/10.1186/1756-0500-4-152

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free